Werewolf Therapeutics Inc

NASDAQ:HOWLUnited States

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Contact Information

Headquarters

200 Talcott Avenue, 2Nd FloorWATERTOWN, MA, United States 02472

Phone

617-952-0555

Fax

302-655-5049

Executives

Independent Chairman of the Board

Luke Evnin

President, Chief Executive Officer, Director

Daniel Hicklin

Chief Financial Officer, Treasurer

Timothy Trost

Chief Technology Officer

Chulani Karunatilake

Chief Medical Officer

Randi Isaacs